

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **M.10826 - GOLDMAN SACHS / NORGINE**

### **SECTION 1.2**

#### **Description of the concentration**

On 24 August 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No. 139/2004 by which The Goldman Sachs Group, Inc. (“**Goldman Sachs**”), through certain investment vehicles indirectly controlled by Goldman Sachs, intends to acquire sole control of Norgine Europe B.V. (“**Norgine**”) and its direct and indirect subsidiaries), and together with Norgine, the “**Norgine Group**”) within the meaning of Article 3(1)(b) of Council Regulation (EC) No 139/2004 (the “**Transaction**”). Goldman Sachs’s investment in Norgine does not include Norgine Ventures B.V. and its direct and indirect subsidiaries (“**Norgine Ventures**”), which will be carved out from Norgine prior to completion of the Transaction.

Following the implementation of the Transaction, Goldman Sachs will indirectly solely control Norgine. The Transaction will be implemented by the acquisition of shares in Norgine by a special purpose vehicle indirectly controlled by Goldman Sachs.

Goldman Sachs is a global investment banking, securities and investment management firm that provides a range of banking, securities and investment services worldwide to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals.

The Norgine Group, which is headquartered in the Netherlands, is a European specialist pharmaceutical company that develops, manufactures, and markets pharmaceutical goods mainly for the following therapeutic areas: gastroenterology, hepatology, emergency care, haematology, obstetrics, cardiology, oncology, urology, and neurology. Currently, Norgine is controlled by the Sellers.